Context: Most pediatric thyroid nodules are cytologically benign, but few data exist to guide treatment.
T hyroid nodules occur in ;1% to 2% of children (1) (2) (3) . Although the prevalence of malignancy in thyroid nodules is higher in children (22% to 27%) than in adults (5% to 10%), most pediatric nodules are benign (4) (5) (6) (7) (8) . Ultrasound-guided fine-needle aspiration (FNA) is recommended to distinguish benign and malignant pediatric nodules (8, 9) , and cytological evaluation can assess malignancy risk and guide resection of nodules with substantial risk of malignancy (10) (11) (12) . For children with cytologically benign nodules, ultrasound surveillance is recommended for the possibility of falsely benign cytology (3% to 5%), although this estimate is based partly on extrapolation from adult studies, because of the limited pediatric data available (8) (9) (10) (11) (13) (14) (15) (16) . Furthermore, although recommendations for surveillance of cytologically benign nodules in adults are based on studies of natural history and outcomes (15) (16) (17) (18) (19) , minimal data exist to guide monitoring of these nodules in children.
Documenting the natural history of pediatric thyroid nodules is challenging because most are diagnosed in adolescence, and patients may be lost to follow-up upon transition to adult care. Our thyroid nodule clinic, based jointly at a children's hospital and an adult hospital, offers a unique opportunity for longitudinal assessment of thyroid nodules through childhood and often into adulthood. Moreover, our clinic uses a standardized assessment and management plan that facilitates uniform data collection on all patients (4) . Here, we report the natural history and outcomes of all cytologically benign thyroid nodules in children evaluated in our clinic over 19 years, which, to our knowledge, represents the largest and most extensively analyzed consecutive cohort of such nodules yet reported. We confirm a low false-negative rate of benign cytology in children, similar to that in adults. We also demonstrate an increased rate of malignancy in nodules .4 cm or that grow during followup, and propose a clinical approach to detecting malignancies missed by initial FNA. Finally, we provide evidence in children for individualizing the interval of initial surveillance of these nodules on the basis of their sonographic characteristics. These insights may inform practice regarding the optimal surveillance and management of cytologically benign thyroid nodules in children.
Patients and Methods

Patients
We reviewed the medical records of all pediatric patients (#18 years old) who underwent ultrasound-guided FNA of a thyroid nodule in the thyroid nodule clinic at Boston Children's Hospital and Brigham and Women's Hospital between January 1998 and November 2016, and we identified all nodules with benign FNA cytology. Thyroid ultrasound was performed by one of 10 radiologists with expertise in thyroid ultrasonography, and reported using the UltraSTAR structured data entry system (20) . In general, FNA was recommended for all nodules $1 cm in diameter that were not purely cystic (even when multiple nodules were present). FNA was performed under ultrasound guidance by one of six thyroidologists using a 25-gauge 1.5-inch (3.8 cm) needle, and aspirates were processed using ThinPrep liquid cytology preparation (Hologic, Marlborough, MA). Cytology was interpreted by a Brigham & Women's Hospital cytopathologist and reported according to the Bethesda System for Reporting Thyroid Cytopathology (21) . Although part of the study period predates the formal introduction of this system, all cytopathologists used diagnostic criteria and terminology that were later adopted by the Bethesda System. All consecutive patients with a cytologically benign thyroid nodule were analyzed, including those with risk factors for thyroid neoplasia (i.e., history of nonthyroid malignancy, radiation exposure, or a genetic risk syndrome). All cytologically benign nodules in each patient were analyzed individually. We included nodules that were benign on repeated FNA after a previous aspirate was reported as nondiagnostic or atypia of undetermined significance (AUS). In general, ultrasound follow-up was recommended in 12 months for cytologically benign nodules that were not resected.
Data collection
Patient characteristics and medical and family histories were abstracted from the medical record. For each nodule, sonographic features [including size, cystic content (solid, 1% to 25%, 25% to 50%, 50% to 75%, or .75%), and the presence of other nodules], cytopathology, and histopathology were collected from the medical record. Ultrasound images were reviewed by a radiologist (D.M.R.) if needed to clarify ultrasound reports. Histopathology of resected nodules reported to be malignant was reviewed by a thyroid pathologist (M.H.), except one case in which the specimen was unavailable.
The follow-up interval for each nodule extended from initial benign FNA to either surgical resection or the most recent thyroid ultrasound. Nodules were included in the analysis if they were resected or had at least six months of ultrasound follow-up. A nodule was considered to be in a multinodular gland if at least one other nodule .5 mm was present. Nodule volume was calculated as length 3 width 3 height 3 p/6. Clinically significant nodule growth was defined as a $50% increase in volume. Analyses of nodule growth included only nodules with at least two ultrasounds. To assess mortality, the date of each patient's last clinical encounter in the medical record was recorded. Study data were managed using REDCap Software, version 7.6.1 (projectredcap.org/software/) (22) .
Statistical analysis
Data were analyzed using Fisher exact or x 2 analysis for categorical variables, or Student t test (parametric) or Mann-Whitney U test (nonparametric) for continuous variables. Associations between continuous variables and outcomes were assessed by linear or logistic regression. Spearman correlation was used for nonparametric outcomes. Multiple regression was performed using variables associated with P , 0.2 in univariate analysis. To analyze the likelihood of nodule growth at first ultrasound follow-up, we performed logistic regression with $50% increase in volume as the dichotomous outcome. A simple logistic model was first constructed with follow-up interval as the sole predictor. Potential predictors added in multiple logistic regression were sex, nodule size, cystic content, multinodularity, and interactions among these variables. Size and cystic content were treated as continuous and ordinal variables, respectively, in model building but dichotomized for graphical depiction of the results (,2 cm or $2 cm diameter; ,25% or $25% cystic content). Patients with risk factors for thyroid neoplasia were excluded from analysis of nodule growth because they were few and preliminary analyses showed a complex relationship between these factors and nodule growth. Two-tailed P values ,0.05 were considered significant. Analyses were performed using SPSS Statistics, version 24 (IBM, Armonk, NY) and SAS, version 9.4 (SAS Institute, Cary, NC) software. This study was approved by the institutional review boards of both institutions.
Results
Patient and nodule characteristics and follow-up
We identified 291 cytologically benign thyroid nodules in 224 patients during the study period. Of these, 237 nodules in 181 patients met inclusion criteria (Table 1) , and 54 nodules in 43 patients were excluded because of insufficient follow-up. Patients with excluded nodules were slightly older (17.2 vs 15.6 years; P = 0.006) but otherwise were similar to included patients. Most patients were female, and a minority had a history of nonthyroid malignancy, radiation exposure, or genetic risk, including mutations in PTEN (n = 8) or DICER1 (n = 1). Fourteen patients had both prior malignancy and radiation exposure. Median nodule diameter was 1.9 cm (range, 0.9 to 7.8 cm); five nodules were ,1 cm (all 0.9 cm). Nearly half of patients (48.1%) had at least one other nodule .5 mm, and multinodularity was more common in patients with genetic risk (89% vs 46%; P = 0.02).
Overall, 84 of 237 nodules (35.4%) in 60 patients were resected a median of 1.2 years (range, 0.1 to 9.0 years) after benign FNA (Fig. 1) . Thirty-six of these cytologically benign nodules were resected without additional imaging. Most nodules were resected because of large size and/or symptoms (30 of 84; 35.7%), or because of abnormal cytology detected either on repeated FNA or in a separate coexisting thyroid nodule (15 of 84; 25%). The remaining 153 nodules in 121 patients were observed by ultrasound for a median of 3.4 years (range, 0.5 to 13.9 years) until a median age of 19.3 years (range, 6.4 to 29.1 years). Ultrasound surveillance extended for $3 years in 54% of nodules (82 of 153), and for $5 years in 24% of nodules (37 of 153). There were no deaths in the study cohort during a median of 4.2 years (range, 0.2 to 15.4) after benign FNA, corresponding to median follow-up age 20.1 years (range, 7.4 to 33.5). One patient excluded from analysis due to insufficient follow-up died of rhabdomyosarcoma that was diagnosed before discovery of his thyroid nodule.
Repeated FNA
Among nodules with at least one follow-up ultrasound, a second FNA was performed in 41 of 201 (20.4%) after a median of 1.7 years (range, 0.6 to 9.9 years). The most frequent indication for second FNA was an increase in nodule size (83%; 34 of 41). In multivariate analysis, nodule characteristics associated with increased odds of undergoing repeated FNA included larger initial diameter (OR, 2.5 per cm; 95% CI, 1.5 to 4.3; P = 0.001), ,25% cystic content (OR, 1.6; 95% CI, 1.02 to 2.5; P = 0.04), and clinically significant growth at first follow-up ultrasound (OR, 7.6; 95% CI, 3.2 to 18.3; P , 0.001).
Nodule cytology on second FNA was benign in 78% (n = 32), indeterminate in 12% (n = 4 AUS; n = 1 suspicious for follicular neoplasm), and nondiagnostic in 10% (n = 4); no nodules were suspicious for papillary carcinoma or malignant on second FNA (Fig. 2) . In nodules rebiopsied because of interval growth, malignancy was diagnosed in three of 34 (8.8%). Among nodules with two benign cytology results, five were followed for ,6 months; 27 were followed for a median of 3.6 years (range, 1.0 to 13.2 years) after the second FNA, and malignancy was diagnosed in one (3.7%) 7 years after initial benign FNA. One solitary nodule with AUS cytology on repeated FNA had had a prior AUS result before the benign cytological result that qualified for inclusion in this study, and this nodule was malignant on resection. Eight other nodules had had an aspirate with AUS cytology before inclusion in this study: Three of these were benign on surgical resection and five were followed by ultrasound for a median of 0.8 years (range, 0.5 to 8.7 years).
Outcomes of cytologically benign nodules
Among 237 cytologically benign nodules, 84 were resected and malignancy was diagnosed in six (2.5%) in six patients (Table 2) . Two nodules were resected immediately due to their large size (.4 cm). Three nodules were resected for abnormal cytology on second FNA, which was performed 1.1 to 1.8 years after initial FNA because of nodule growth (n = 2, both with AUS cytology on repeated FNA) or newly diagnosed thyroid cancer in the family (n = 1, cytology suspicious for follicular neoplasm on repeated FNA). The remaining patient had received total body irradiation at age 2 years for neuroblastoma and external beam radiation (25 Gy) to the neck for synovial sarcoma at age 9 years. This patient's nodule underwent multiple FNAs for interval growth and intermittent AUS cytology ultimately prompted resection, which resulted in malignancy being diagnosed 7.3 years after initial benign FNA. The six thyroid cancers comprised three encapsulated follicular variants of papillary thyroid cancer, one invasive follicular variant of papillary thyroid cancer, and two minimally invasive follicular carcinomas. Although two cancers showed lymphovascular invasion, no patient had evidence of extrathyroidal extension or local or distant metastasis. All patients underwent total thyroidectomy and radioiodine therapy (52 to 77 mCi), and all were alive with no evidence of disease (unstimulated thyroglobulin concentration ,0.2 ng/mL with negative imaging) a median of 4.9 years (range, 3.0 to 9.0 years) after diagnosis.
Nodule characteristics associated with increased risk of malignancy included diameter .4 cm Outcomes of patients undergoing repeated FNA of a thyroid nodule with initial benign cytology. *Other sonographic changes: development of more pronounced solid component (n = 2), calcifications (n = 1), or increased vascularity (n = 1); or technical difficulty in following multiple nodules (n = 2). **Repeated FNA performed because of a new diagnosis of thyroid cancer in patient's mother. †Cytopathology: Four AUS, one suspicious for follicular neoplasm. † †Patient had been treated with total body irradiation at age 2 y and external beam radiation to the neck (25 Gy) at age 9 y. † † †Patients lost to follow-up, no additional information available.
significant growth at first ultrasound follow-up [6.0% (three of 50) vs 0.7% (one of 151); P = 0.048]. History of prior AUS cytology, nonthyroid malignancy, radiation exposure, or a genetic syndrome was not associated with risk of malignancy. No thyroid cancer was diagnosed in 17 cytologically benign nodules in nine patients with genetic syndromes.
Growth of cytologically benign nodules
The pattern of growth was analyzed in 163 nodules in 131 patients without risk factors for thyroid neoplasia. The first follow-up ultrasound was performed a median of 11 months (range, 1 to 78 months) after benign FNA. Clinically significant growth was observed at first followup in 39 of 163 nodules (24%), and the likelihood of growth was directly related to the follow-up interval (P = 0.004; Fig. 3 ). The model-derived estimated probability (6SE) of clinically significant growth at first follow-up was 15% 6 3% at 6 months, 24% 6 4% at 12 months, and 49% 6 10% at 24 months.
A higher likelihood of clinically significant growth was observed in nodules with lower cystic content (P = 0.03) and in nodules in a multinodular gland (P = 0.06). The relationship of nodule growth to initial size was influenced by cystic content (P for interaction = 0.02). In predominantly solid nodules (i.e., ,25% cystic) larger initial size was associated with more rapid growth, whereas in more-cystic nodules (i.e., $25% cystic), larger size was associated with slower growth. In this analysis of nodules followed by ultrasound in patients without risk for thyroid neoplasia, malignancy was diagnosed in three of 73 solitary nodules (4.1%; two of the three grew at first follow-up); all three of these nodules were ,25% cystic. No malignancy was diagnosed among nodules in a multinodular gland (none of 90) over a median follow-up of 34.7 months (range, 2.7 to 133.8 months). Clinically significant growth at first followup was not statistically associated with malignancy (P = 0.14). This remained true in the subset of nodules in a multinodular gland (in which no malignancies were diagnosed; P = 1); however, among solitary nodules, clinically significant growth at first follow-up was associated with a borderline increase in malignancy risk (OR, 12; 95% CI, 0.99 to 145; P = 0.07).
Of 163 nodules examined for pattern of growth, 59 (36.2%) exhibited clinically significant growth at any time during follow-up, after a median of 15.6 months (range, 2.5 to 78.1). Among these nodules, the time to clinically significant growth was not associated with any patient or nodule characteristic examined, nor with risk of malignancy.
Discussion
Although most pediatric thyroid nodules that undergo FNA have benign cytology (4, 11) , current guidelines acknowledge a lack of pediatric-specific data to support many recommendations for the management of these nodules (9) . This analysis, to our knowledge the largest and most extensive single-center consecutive cohort of cytologically benign pediatric nodules reported to date, provides important insights into the natural history and outcomes of these nodules that address many existing knowledge gaps.
The most important characteristic of a benign cytologic result is its false-negative rate, which reflects the confidence with which malignancy can be excluded. Current guidelines cite a false-negative rate of 3% to 5% in children, based primarily on a meta-analysis of 12 studies that included 347 cytologically benign nodules (9, 10) . Several studies in this meta-analysis, however, included patients up to 21 years old, and many (including the largest single study) analyzed only resected nodules, which overestimates false-negative rates. The false-negative rate of benign cytology in our cohort of pediatric nodules (2.5%) is similar to that in adults (1% to 4%) (14, (23) (24) (25) (26) . The reliability of this estimate is enhanced by our inclusion of pediatric patients only and by the unique structure of our program, which allowed extended follow-up of a significant proportion of patients, in most cases into adulthood.
Studies in adults have shown a higher false-negative rate in nodules .4 cm (10% to 13%) than in smaller nodules (27, 28) , but this has not been evaluated in a large pediatric series. Our analysis confirms a high false-negative rate (two of 13; 15.4%) in pediatric nodules .4 cm. Although the number of such nodules in our cohort is small (13 of 237; 5.5%), this finding supports the current recommendation to consider resection of pediatric thyroid nodules .4 cm even with a benign cytological result (9) . In our cohort, solitary nodules were more likely than nodules in a multinodular gland to harbor malignancy, which is consistent with data from adults (29) . Although the study by Frates et al. (29) included nodules .1 cm regardless of cytology, the greater likelihood of malignancy in solitary nodules may hold true in the subset with benign cytology. Notably, in our overall cohort, only one of 143 cytologically benign nodules in a multinodular gland proved to be malignant (0.7%), and this nodule was resected immediately because of its large size (.4 cm) at presentation.
All six thyroid cancers in our cohort were relatively indolent. Although two had lymphovascular invasion, none had local or distant metastasis, and all patients were disease free at last follow-up. This is consistent with a study of adults in which 1.3% of cytologically benign nodules were found to be malignant, but none resulted in significant morbidity or mortality (17) . Thus, patients and clinicians can be reassured that even if malignancy is later detected in a nodule with initial benign cytology, it likely can be treated successfully with minimal risk of adverse outcome.
One-fifth of cytologically benign nodules in our cohort underwent repeated FNA, usually for interval growth. Moreover, a $50% increase in volume at first follow-up ultrasound was an indicator of possible malignancy. Half of malignancies (three of six) were detected by repeated FNA performed for interval growth, and among nodules rebiopsied for growth, the rate of malignancy was significant (8.8%). One additional malignancy was detected after a new diagnosis of thyroid cancer in a first-degree relative. These results support that nodule growth may be an indication to consider repeated FNA, and that increased caution may be warranted in patients in whom a new family history of thyroid cancer is elicited. This approach, combined with resection of nodules .4 cm, is likely to detect most falsenegative cytological results in pediatric thyroid nodules. Importantly, although interval growth increases the odds of malignancy in a cytologically benign nodule, the absolute risk of malignancy remains low. This emphasizes that growth is characteristic of benign and malignant nodules, and, therefore, growth alone is a weak predictor of malignancy (8, 18, 19) .
In adults, no further monitoring is recommended for thyroid nodules with two benign cytological results (15, 23, 25, 30) . In our cohort, 26 of 27 such nodules (96%) had no thyroid cancer diagnosed during follow-up. The only malignancy was discovered 7 years after initial benign FNA in a patient with prior malignancy and significant radiation exposure. Thus, pediatric thyroid nodules that are twice benign on FNA appear unlikely to be malignant, particularly in patients without risk factors for thyroid neoplasia. However, given the small number and follow-up duration of such nodules in our cohort, these data are not sufficient to support discontinuing ultrasound surveillance, although less-frequent surveillance may be reasonable.
In our cohort, a history of nonthyroid malignancy, radiation exposure, or a genetic risk syndrome was not associated with increased risk of malignancy. This suggests that a benign cytological result is generally as reliable in children with these risk factors as in those without. Nevertheless, the small numbers of such patients and of malignancies in our cohort may not provide sufficient power to detect small differences in risk. Therefore, until more data are available, continued caution and surveillance seem advisable in patients with risk factors.
Adult guidelines recommend individualizing followup intervals for cytologically benign nodules based on ultrasonographic risk level (8) . In contrast, minimal data exist to ascertain the optimal follow-up interval in children and whether this depends on nodule characteristics. Therefore, we sought to determine what interval of initial surveillance yields a significant likelihood of detecting a change that would alter management (i.e., a $50% increase in volume, which is an indication to consider repeated FNA and conveys an increased risk of malignancy). Among patients without risk factors for thyroid neoplasia, the likelihood of detecting clinically significant growth was low at 6 months (15%) and even 12 months (24%) after initial FNA, but increased to 49% by 24 months. These estimates were significantly modified by nodule characteristics including initial size, cystic content, and thyroid multinodularity. In general, morecystic nodules grew more slowly, as is true in adults (31) . The effect of initial size on growth depended on cystic content: In solid or minimally cystic (,25%) nodules, larger size was associated with more rapid growth, whereas among more-cystic nodules, larger nodules grew more slowly. These results provide a basis for individualizing the timing of initial ultrasound follow-up after benign FNA based on nodule characteristics. Repeated ultrasound before 12 months appears unlikely to alter management in most cases. For solitary small nodules (i.e., ,2 cm), repeated ultrasound at 12 months affords a 10% to 30% chance of observing clinically significant growth that might prompt reaspiration. For solitary nodules .2 cm, a similar interval appears appropriate if the nodule is ,25% cystic, but deferring monitoring up to 24 months may be reasonable in more-cystic nodules. Nodules in a multinodular gland grow faster than solitary nodules, but because their risk of malignancy is significantly lower, more-frequent ultrasound surveillance is unlikely to improve patient outcomes. Although the precision of these estimates is limited by the size of the cohort on which the model is based, they provide a starting point for rationalizing the recommended timing of surveillance for cytologically benign nodules in children.
Importantly, our analysis did not reveal any patient or nodule characteristics that predict clinically significant growth after the first follow-up ultrasound. Therefore, our data shed little light on when (if ever) surveillance of cytologically benign pediatric nodules may be discontinued.
This study has several limitations. Although our cohort of cytologically benign pediatric thyroid nodules is large, its size may still limit our ability to detect small differences. Because our institution is a tertiary referral center, selection bias for higher-risk patients may be present. However, only 19 of 181 patients (10.5%) underwent FNA at another institution before evaluation in our center, and none of these was diagnosed with thyroid cancer, so such bias is likely minimal. Patients without sufficient data for analysis were slightly older than included patients, probably because older patients were more likely to transition to adult care-potentially at a different facility-before first follow-up. These patients did not differ in any other respect from included patients, however, so their exclusion is unlikely to have introduced significant bias. Finally, although follow-up extended into adulthood in most patients, and for .5 years in one-quarter of nodules, longer follow-up would provide additional confidence in the absence of malignancy in unresected nodules.
In summary, this study provides important insights that may inform practice regarding optimal surveillance and management of cytologically benign pediatric thyroid nodules. Benign cytology in children has a low falsenegative rate and conveys an excellent prognosis even if malignancy is later diagnosed. Nodules .4 cm have a higher risk of false-negative cytology and their resection should be considered; surveillance of smaller nodules for interval growth or a change in family history should detect most remaining thyroid cancers missed by initial FNA. We also provide pediatric evidence for individualizing the interval of initial ultrasound surveillance based on nodule characteristics. Additional studies are needed to validate these findings to further guide optimal management of children with cytologically benign nodules.
